UK medication update · David Scott Dietitian
GLP-1 medicines in the UK: updates to know about
A source-linked digest of recent UK regulatory and safety updates, checked against MHRA publications on 29 October 2026.
Sources checked 29 October 2026
UK authorisations are product-specific
The MHRA announced approval of a semaglutide (Wegovy) tablet for weight management on 11 June 2026. On 10 August 2026, it announced authorisation of orforglipron (Foundayo) for weight management and type 2 diabetes. A medicine’s authorisation covers specific products and uses; it does not decide an individual prescription or NHS access.
GLP-1 medicines are prescription-only. The MHRA’s current public guidance explains licensed uses, safe access and where to find updated information. Check the linked guidance rather than relying on headlines or unofficial sellers.
Safety updates to discuss with a prescriber
On 29 January 2026, the MHRA strengthened product-information warnings about acute pancreatitis for GLP-1 and dual GLP-1/GIP receptor agonists, including rare reports of severe outcomes. On 5 February 2026, it published a separate update about a very rare risk of non-arteritic anterior ischaemic optic neuropathy (NAION) associated with semaglutide.
Read the full MHRA notices for the advice and context. If you take one of these medicines, speak to your prescriber about personal concerns. Do not change treatment based on this summary.
Sources and further reading
- MHRA: GLP-1 medicines for weight loss and diabetes — what you need to know
- MHRA: First GLP-1 tablet for weight loss approved in the UK
- MHRA: UK authorises orforglipron for weight management and type 2 diabetes
- MHRA: Strengthened warnings on acute pancreatitis
- MHRA: Semaglutide and the very rare risk of NAION
- NHS England: Weight management injections